Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aeterna Phase III Impavido skin disease data

Aeterna (TSE:AEL; AELA) said that in a double-blind Phase III trial in patients with

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE